Metformin Crescent Pharma

Metformin Hydrochloride, the active ingredient in Metformin Crescent Pharma, is a biguanide presented as an unknown/unknown for oral use. It reduces hepatic glucose production and improves insulin sensitivity, treating type 2 diabetes mellitus in adult patients.

GNH USA supplies Metformin Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Crescent Pharma is a biguanide indicated for disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to improve glycaemic control. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes by enhancing insulin sensitivity. - Polycystic ovary syndrome: reduces insulin resistance and may help normalize menstrual cycles.

Metformin Crescent Pharma may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight in some patients.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Vitamin B12 deficiency: may develop with long‑term therapy. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Metformin Crescent Pharma, consider the following safety measures. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic impairment: avoid use in patients with significant liver disease. - Cardiovascular status: monitor for signs of heart failure, especially during acute illness. - Alcohol consumption: advise patients to limit intake to reduce lactic acidosis risk. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Metformin Crescent Pharma can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance renal effects, monitor kidney function. - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - Alcohol: potentiates lactic acidosis risk. - Antiretroviral agents (e.g., protease inhibitors): may increase metformin levels.